FDA under fire: Data discrepancies uncovered in AstraZeneca approval trials
Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca’s multibillion-dollar heart drug. A new BMJ investigation reveals data discrepancies, missing lab readings, and questions about the integrity of the trial process. Notably, key results reported in a major cardiology journal were inaccurately presented, and some study contributors were omitted …
FDA under fire: Data discrepancies uncovered in AstraZeneca approval trials Read More »